Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Dermata Therapeutics Inc. Warrant (DRMAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: DRMAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.57 | 52 Weeks Range 0.01 - 0.03 | Updated Date 06/14/2025 |
52 Weeks Range 0.01 - 0.03 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -95.9% | Return on Equity (TTM) -206.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4154323 |
Shares Outstanding - | Shares Floating 4154323 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Dermata Therapeutics Inc. Warrant
Company Overview
History and Background
Dermata Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing innovative, first-in-class, dermatology and aesthetic products.
Core Business Areas
- Dermatology Therapeutics: Focuses on developing treatments for common skin conditions, including acne, rosacea, and psoriasis.
- Aesthetic Products: Explores and develops products aimed at improving skin appearance and addressing aging concerns.
Leadership and Structure
Dermata Therapeutics has a leadership team comprising individuals with experience in pharmaceutical development and commercialization. Structure includes a Board of Directors and executive management team responsible for strategy and operations.
Top Products and Market Share
Key Offerings
- DMT310 (Topical Spironolactone): A topical treatment being developed for acne and rosacea. Currently in clinical trials. Market share is not yet applicable as it's in development. Competitors include topical retinoids (tretinoin, adapalene), benzoyl peroxide, and oral medications like isotretinoin.
- DMT410: A sebum modulating compound. Market share is not yet applicable as it's in development. Competitors include brands such as L'Oreal and P&G
Market Dynamics
Industry Overview
The dermatology market is characterized by increasing demand for effective treatments for skin conditions and aesthetic procedures. It is competitive, with both established pharmaceutical companies and smaller biotech firms vying for market share.
Positioning
Dermata Therapeutics aims to differentiate itself by developing innovative, first-in-class therapies that address unmet needs in dermatology and aesthetics.
Total Addressable Market (TAM)
The global dermatology market is substantial, estimated to be worth tens of billions of dollars annually. Dermata's positioning focuses on specific segments within this larger market, particularly acne and rosacea.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Experienced management team
- Focus on unmet needs in dermatology
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Lack of commercialized products
Opportunities
- Potential for partnerships or acquisitions
- Expansion into new dermatology indications
- Positive clinical trial results
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- LEO
- GALD
- Bausch Health Companies Inc. (BHC)
Competitive Landscape
Dermata Therapeutics faces competition from established pharmaceutical companies and other biotech firms developing dermatology products. Its advantage lies in novel drug candidates, while its disadvantage lies in limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in clinical trials and securing funding.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential FDA approval of its drug candidates.
Recent Initiatives: Recent initiatives include advancing clinical trials for DMT310 and DMT410, and exploring potential partnerships.
Summary
Dermata Therapeutics is a clinical-stage biopharmaceutical company with promising novel drug candidates targeting unmet needs in dermatology. Its success hinges on positive clinical trial results and securing funding for further development and commercialization. While the company possesses innovative technology, it needs to navigate a highly competitive market and regulatory hurdles to achieve its growth potential. The warrant is speculative, offering potential upside if the company succeeds, but carrying significant risk due to its development stage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Dermata Therapeutics Inc. website
- SEC filings
- Industry reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not investment advice. Investing in biotech companies is highly speculative and involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dermata Therapeutics Inc. Warrant
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-08-13 | Founder, President, CEO & Chairman Mr. Gerald T. Proehl | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.dermatarx.com |
Full time employees 8 | Website https://www.dermatarx.com | ||
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.